Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (43)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tai, T. L.
Right arrow Articles by Barry, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tai, T. L.
Right arrow Articles by Barry, M.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2002; 41: 951-952
© 2002 British Society for Rheumatology

Letters to the Editor

Pneumocystis carinii pneumonia following a second infusion of infliximab

T. L. Tai, K. P. O'Rourke, M. McWeeney1, C. M. Burke1, K. Sheehan and M. Barry

Departments of Rheumatology and 1Respiratory Medicine, James Connolly Memorial Hospital, Blanchardstown, Dublin 15, Ireland

The first 10% of the full text of this article appears below.

SIR, Anti-tumour necrosis factor {alpha} (TNF-{alpha}) blockade is increasingly used for severe rheumatoid arthritis (RA). There is an increased risk of infection, including atypical infection [1] associated with TNF-{alpha} blockade. We report the development of Pneumocystis carinii pneumonia (PCP) in a man with RA shortly after commencing therapy with the anti-TNF-{alpha} agent infliximab (Remicade). This occurred in the setting of concomitant therapy with low-dose weekly methotrexate and corticosteroids.

A 49-yr-old man who had had seropositive RA for 9 yr . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
C. Sheehy, E. Murphy, and M. Barry
Effective co-administration of infliximab and etanercept following the failure of sequential anti-TNF agents in a patient with HLA-B27-associated arthropathy
Rheumatology, October 1, 2006; 45(10): 1314 - 1315.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
I. Marie, P. Heliot, F. Roussel, F. Herve, J. F. Muir, and H. Levesque
Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab
Rheumatology, September 1, 2005; 44(9): 1201 - 1202.
[Full Text] [PDF]

Home page
 Infect. Immun.Home page
A. C. Herring, N. R. Falkowski, G.-H. Chen, R. A. McDonald, G. B. Toews, and G. B. Huffnagle
Transient Neutralization of Tumor Necrosis Factor Alpha Can Produce a Chronic Fungal Infection in an Immunocompetent Host: Potential Role of Immature Dendritic Cells
Infect. Immun., January 1, 2005; 73(1): 39 - 49.
[Abstract] [Full Text] [PDF]

Home page
 J Intensive Care MedHome page
J. T. Giles and J. M. Bathon
Serious Infections Associated with Anticytokine Therapies in the Rheumatic Diseases
J Intensive Care Med, November 1, 2004; 19(6): 320 - 334.
[Abstract] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
M. Rodriguez and J. A. Fishman
Prevention of Infection Due to Pneumocystis spp. in Human Immunodeficiency Virus-Negative Immunocompromised Patients
Clin. Microbiol. Rev., October 1, 2004; 17(4): 770 - 782.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
E. Molloy, S. Ramakrishnan, E. Murphy, and M. Barry
Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab
Rheumatology, April 1, 2004; 43(4): 522 - 523.
[Full Text] [PDF]